B03 CARFILZOMIB AND LENALIDOMIDE FOR PRIMARY PLASMA CELL LEUKEMIA: FINAL RESULTS OF THE PROSPECTIVE PHASE 2 EMN12/HOVON-129 STUDY FOR PATIENTS AGED ≥66 YEARS

• P. Musto,
• M.C. Minnema,
• W.W.H. Roeloffzen,
• A. Capra,
• B. van der Holt,
• A. Juul Vangsted,
• A. Broyl,
• F. Schjesvold,
• T. Lund,
• T. Silkjaer,
• R. Benjamin,
• M. Grasso,
• K. Lung Wu,
• J. Caers,
• M. Cavo,
• R. Hájek,
• B. Bruno,
• A. Gadisseur,
• G. Pietrantuono,
• M. Offidani,
• L. Pour,
• P. Sonneveld,
• M. Boccadoro,
• N. van de Donk

Affiliations

P. Musto

1 Department of Precision and Regenerative Medicine and Ionian Area, “Aldo Moro” University School of Medicine, and Hematology and Stem Cell Transplantation Unit, AOU Consorziale Policlinico, Bari, Italy

M.C. Minnema

2 University Medical Center Utrecht, Department of Hematology, Utrecht University, Utrecht, the Netherlands

W.W.H. Roeloffzen

3 Department of Hematology, University Medical Center Groningen, University Groningen, Groningen, the Netherlands

A. Capra

4 Division of Hematology, University of Torino, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Torino, Italy

B. van der Holt

5 HOVON Data Center, Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands

A. Juul Vangsted

6 Dept. Hematology, Rigshospitalet, Copenhagen University, Copenhagen, Denmark

A. Broyl

7 Department of Hematology, Erasmus Medical Center, Rotterdam, the Netherlands

F. Schjesvold

8 Oslo Myeloma Center, Department of Hematology, Oslo University Hospital and KG Jebsen Center for B cell malignancies, University of Oslo, Oslo, Norway

T. Lund

9 Odense Hospital, Odense, Denmark

T. Silkjaer

10 Aarhus University Hospital, Aarhus, Denmark

R. Benjamin

11 King’s College Hospital, London, United Kingdom

M. Grasso

12 Azienda Ospedaliera S. Croce e Carle, Cuneo, Italy

K. Lung Wu

13 Department of Hematology, ZNA Stuivenberg, Antwerp, Belgium

J. Caers

14 Department of Hematology, CHU Liege

M. Cavo

15 IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia “Seràgnoli”, Bologna, Italy

R. Hájek

16 Department of Hematooncology, University Hospital Ostrava and Department of Hematooncology, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic

B. Bruno

17 Division of Hematology, Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy

A. Gadisseur

18 Department of Haematology, Antwerp University Hospital, Edegem, Belgium

G. Pietrantuono

19 Centro di Riferimento Oncologico della Basilicata (IRCCS-CROB), Rionero in Vulture, Italy

M. Offidani

20 AOU Ospedali Riuniti di Ancona, Ancona, Italy

L. Pour

21 Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, Brno, Czech Republic

P. Sonneveld

22 Erasmus MC Cancer Institute, Department of Hematology, Rotterdam, the Netherlands

M. Boccadoro

4 Division of Hematology, University of Torino, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Torino, Italy

N. van de Donk

23 Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Hematology, Cancer Center Amsterdam, Amsterdam, the Netherlands